Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting
May 26 2022 - 8:15AM
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life
sciences company focused on developing treatments for adult and
pediatric cancers with potential for Orphan Drug Designation, while
also commercializing diagnostics, announces that two abstracts
featuring the Company’s RAS inhibitor program will be featured in
the American Society for Clinical Oncology’s (ASCO) Annual Meeting
Abstract Book, which was released online today.
Michael Poirier, Qualigen's Chairman and CEO,
commented, “We believe that this recognition from ASCO is an
important step for our RAS inhibitor program and demonstrates that
there is indeed significant scientific interest in our program and
research approach in collaboration with the University of
Louisville Research Foundation. We are focused on identifying a
lead candidate for IND-enabling studies in Q4 of this year and look
forward to sharing our advances as we progress toward that
goal.”
The two abstracts, which can be found in the
ASCO Annual Meeting Abstract Book include:
Title: |
A Novel
RAS Inhibitor for Pancreatic Cancer |
Authors/Affiliation: |
Clark,
et., al. University of Louisville, Louisville, KY |
Highlights: |
Qualigen’s pan-RAS inhibitor (RAS-F) was screened to determine
inhibition against pancreatic cancer, which has a dismal survival
rate, and is most closely associated with activating mutations in
the RAS oncoprotein. Approximately 90% of pancreatic
adenocarcinomas carry point mutations activating RAS. RAS-F binds
all three main isoforms of RAS at low uM kd and modulates the RAS
effector domain in NMR studies. It suppresses RAS signaling
pathways in transient assays and suppresses pancreatic tumor cell
growth in soft agar with IC50s below 500nM. It suppresses xenograft
development of human and mouse RAS driven pancreatic tumor cell
lines and reduces the growth of a pancreatic cancer PDX. RAS-F is a
pre-clinical pan-RAS inhibitor that is active in vitro and in vivo
against pancreatic cancer models. |
|
|
Title: |
A Novel
Pan-RAS Inhibitor for Malignant Peripheral Nerve Sheath Tumors |
Authors/Affiliation: |
Clark,
et. al., University of Louisville, Louisville, KY |
Highlights: |
Qualigen’s pan-RAS inhibitor (RAS-F) was screened to determine
inhibition against malignant peripheral nerve sheath tumors
(MPNST), a rare but deadly form of sarcoma originating from the
Schwann cell compartment. RAS-F was shown to bind all three main
isoforms of RAS at low uM kd and modulates the RAS effector domain
in NMR studies. RAS-F was also shown to suppress RAS signaling
pathways in transient assays and suppress MPNST tumor cell growth
in soft agar with IC50 ~250nM. Importantly, RAS-F also suppresses
MPNST PDX growth in vivo. RAS-F is a pre-clinical pan-RAS inhibitor
that is active in vitro and in vivo against MPNST cancer models.
The agent also has potential uses against non-tumor manifestations
of Neurofibromatosis such as Plexiform and Cutaneous
neurofibromas. |
Qualigen’s RAS program is a family of small
molecules designed to prevent mutated RAS gene proteins from
binding to their effector proteins. Exclusively in-licensed from
UofL, compounds from this discovery engine have been shown to
impact tumor growth in multiple in vivo models. Qualigen is
evaluating promising compounds generated from this partnership in
various RAS-driven advanced solid tumors such as pancreatic,
colorectal and lung cancers.
About Qualigen
Therapeutics, Inc.
Qualigen Therapeutics, Inc. is a diversified
life sciences company focused on developing treatments for adult
and pediatric cancer, as well as maintaining and expanding its core
FDA-cleared FastPack® System, which has been used successfully in
diagnostics for over 20 years. Our investigational QN-302 compound
is a small molecule selective transcription inhibitor with strong
binding affinity to G4s prevalent in cancer cells; such binding
could, by stabilizing the G4s against “unwinding,” help inhibit
cancer cell proliferation. Our investigational QN-247 compound
inhibits nucleolin, a key multi-functional regulatory protein that
is overexpressed in cancer cells; QN-247 may thereby be able to
inhibit the cells’ proliferation. QN-247 has shown promise in
preclinical studies for the treatment of acute myeloid leukemia
(AML). The investigational compounds within Qualigen’s RAS-F family
of RAS oncogene protein-protein interaction inhibitor small
molecules are believed to inhibit or block the binding of mutated
RAS genes’ proteins to their effector proteins, thereby leaving the
proteins from the mutated RAS unable to cause further harm. In
theory, such mechanism of action may be effective in the treatment
of about one quarter of all cancers, including certain forms of
pancreatic, colorectal, and lung cancers. In addition to its
oncology drug pipeline, Qualigen has an established diagnostics
business which manufactures and distributes proprietary and highly
accurate rapid blood testing systems to physician offices and small
hospitals for the management of prostate cancer and other diseases
and health conditions.
For more information about Qualigen Therapeutics, Inc., please
visit www.qualigeninc.com.
Forward-Looking Statements
This news release contains forward-looking
statements by Qualigen that involve risks and uncertainties and
reflect the Company's judgment as of the date of this release.
These statements include those related to the Company's prospects
and strategy for its RAS inhibitor program and other therapeutic
drug candidates. Actual events or results may differ from the
Company's expectations. For example, there can be no assurance that
the closing conditions for the NanoSynex transaction will be
satisfied or that the Company will be able to successfully develop
any drugs (including RAS-F, QN-302 and QN-247); that preclinical
development of the Company's drugs (including RAS-F, QN-302 and
QN-247, and the deprioritized infectious-disease drug candidate
QN-165) will be completed on any projected timeline or will be
successful; that any clinical trials will be approved to begin by
or will proceed as contemplated by any projected timeline, or at
all; that any future clinical trial data will be favorable or that
such trials will confirm any improvements over other products or
lack negative impacts; that any drugs will receive required
regulatory approvals (or Fast Track designation or Orphan Drug
status) or that they will be commercially successful; that patents
will issue on the Company's owned and in-licensed patent
applications; that such patents, if any, and the Company's
currently owned and in-licensed patents would prevent competition;
or that the Company will be able to procure or earn sufficient
working capital to complete the development, testing and launch of
the Company's prospective therapeutic products (including RAS-F,
QN-302, QN-247, and QN-165). The Company's stock price could be
harmed if any of the events or trends contemplated by the
forward-looking statements fails to occur or is delayed or if any
actual future event otherwise differs from expectations. Additional
information concerning these and other risk factors affecting the
Company's business can be found in the Company's prior filings with
the Securities and Exchange Commission, including its most recent
annual report on Form 10-K, all of which are available at
www.sec.gov.
The Company disclaims any intent or obligation
to update these forward-looking statements beyond the date of this
news release, except as required by law. This caution is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Contact:
Jules AbrahamJQA Partners, Inc.
917-885-7378jabraham@jqapartners.com
Source: Qualigen Therapeutics, Inc.
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Apr 2024 to May 2024
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From May 2023 to May 2024